A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot

Completed

Conditions studied: Venous Thromboembolism (VTE)

In brief

A study to compare the risk of a major bleeding in participants who received 2 different blood thinning medications following a blood clot

Key facts

Study ID

NCT03521908

Run by

Bristol-Myers Squibb

People needed

35756

Starts

2016-06-13

Expected to finish

2018-11-23

Last updated by the study team

2022-02-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• An acute-care inpatient encounter with a principal or secondarydiagnosis of VTE, or an ambulatory-care encounter with any diagnosis of VTE
• An outpatient pharmacy claim for apixaban or warfarin during the 30-day period following the index encounter
• Continuous and comprehensive medical/drug coverage for ≥6 months preceding the index encounter

You may not qualify if…

• Evidence of a trial fibrillation/flutter or chemotherapy/radiation therapy for malignancy (other than non-melanoma skin cancer) during 6-month period preceding first receipt of index therapy
• Evidence of VTE(VTE event)during 6-month period preceding index encounter
• Evidence of malignancy (other than non-melanoma skin cancer) during 90-day period preceding first receipt of index therapy
• Other protocol defined inclusion/exclusion criteria could apply

Where it is running

• Local Institution — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.